196 related articles for article (PubMed ID: 23821831)
21. Sublingual allergen-specific immunotherapy adjuvanted with monophosphoryl lipid A: a phase I/IIa study.
Pfaar O; Barth C; Jaschke C; Hörmann K; Klimek L
Int Arch Allergy Immunol; 2011; 154(4):336-44. PubMed ID: 20975285
[TBL] [Abstract][Full Text] [Related]
22. Ultra short pre-seasonal subcutaneous immunotherapy and pre-coseasonal sublingual immunotherapy for pollen allergy: an evaluation of patient's preference in real life.
Manzotti G; Pappacoda A; Dimatteo M; Scolari C; Riario-Sforza GG; Incorvaia C
Eur Ann Allergy Clin Immunol; 2013 Aug; 45(4):138-43. PubMed ID: 24067339
[TBL] [Abstract][Full Text] [Related]
23. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis.
Didier A; Malling HJ; Worm M; Horak F; Jäger S; Montagut A; André C; de Beaumont O; Melac M
J Allergy Clin Immunol; 2007 Dec; 120(6):1338-45. PubMed ID: 17935764
[TBL] [Abstract][Full Text] [Related]
24. Grazax: an oral vaccine for the treatment of grass pollen allergy (hay fever).
Allison C; Fraser J
Issues Emerg Health Technol; 2007 Nov; (107):1-4. PubMed ID: 18041171
[TBL] [Abstract][Full Text] [Related]
25. Sublingual or subcutaneous immunotherapy for seasonal allergic rhinitis: an indirect analysis of efficacy, safety and cost.
Dranitsaris G; Ellis AK
J Eval Clin Pract; 2014 Jun; 20(3):225-38. PubMed ID: 24444390
[TBL] [Abstract][Full Text] [Related]
26. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis.
Dahl R; Stender A; Rak S
Allergy; 2006 Feb; 61(2):185-90. PubMed ID: 16409194
[TBL] [Abstract][Full Text] [Related]
27. Effect of sublingual immunotherapy with grass monomeric allergoid on allergen-specific T-cell proliferation and interleukin 10 production.
Burastero SE; Mistrello G; Falagiani P; Paolucci C; Breda D; Roncarolo D; Zanotta S; Monasterolo G; Rossi RE
Ann Allergy Asthma Immunol; 2008 Apr; 100(4):343-50. PubMed ID: 18450120
[TBL] [Abstract][Full Text] [Related]
28. Five-grass pollen 300IR SLIT tablets: efficacy and safety in children and adolescents.
Halken S; Agertoft L; Seidenberg J; Bauer CP; Payot F; Martin-Muñoz MF; Bartkowiak-Emeryk M; Vereda A; Jean-Alphonse S; Melac M; Le Gall M; Wahn U
Pediatr Allergy Immunol; 2010 Sep; 21(6):970-6. PubMed ID: 20718927
[TBL] [Abstract][Full Text] [Related]
29. Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets.
Malling HJ; Lund L; Ipsen H; Poulsen L
J Investig Allergol Clin Immunol; 2006; 16(3):162-8. PubMed ID: 16784009
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of sublingual immunotherapy with grass monomeric allergoid: comparison between two different treatment regimens.
Quercia O; Bruno ME; Compalati E; Falagiani P; Mistrello G; Stefanini GF
Eur Ann Allergy Clin Immunol; 2011 Dec; 43(6):176-83. PubMed ID: 22360134
[TBL] [Abstract][Full Text] [Related]
31. Similar biological activity in skin prick test for Oralair
Larenas Linnemann DE; Singh J; Rosario N; Esch R; Matta JJ; Maspero J; Michels A; Mösges R
Allergy; 2016 Dec; 71(12):1782-1786. PubMed ID: 27484017
[TBL] [Abstract][Full Text] [Related]
32. Towards evidence-based medicine in specific grass pollen immunotherapy.
Calderon M; Mösges R; Hellmich M; Demoly P
Allergy; 2010 Apr; 65(4):420-34. PubMed ID: 20028374
[TBL] [Abstract][Full Text] [Related]
33. Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experience.
Didier A; Wahn U; Horak F; Cox LS
Expert Rev Clin Immunol; 2014 Oct; 10(10):1309-24. PubMed ID: 25205329
[TBL] [Abstract][Full Text] [Related]
34. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE.
Cox LS; Casale TB; Nayak AS; Bernstein DI; Creticos PS; Ambroisine L; Melac M; Zeldin RK
J Allergy Clin Immunol; 2012 Dec; 130(6):1327-34.e1. PubMed ID: 23122534
[TBL] [Abstract][Full Text] [Related]
35. Grazax for hay fever?
BMJ Group
Drug Ther Bull; 2008 Feb; 46(2):9-10. PubMed ID: 18256175
[TBL] [Abstract][Full Text] [Related]
36. GRAZAX®: a sublingual immunotherapy vaccine for Hay fever treatment: from concept to commercialization.
Barber D; Rico P; Blanco C; Fernandez-Rivas M; Ibañez MD; Escribese MM
Hum Vaccin Immunother; 2019; 15(12):2887-2895. PubMed ID: 31157592
[TBL] [Abstract][Full Text] [Related]
37. Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually.
Panzner P; Petrás M; Sýkora T; Lesná I
Respir Med; 2008 Sep; 102(9):1296-304. PubMed ID: 18585908
[TBL] [Abstract][Full Text] [Related]
38. Oralair®: sublingual immunotherapy for the treatment of grass pollen allergic rhinoconjunctivitis.
Hong J; Bielory L
Expert Rev Clin Immunol; 2011 Jul; 7(4):437-44. PubMed ID: 21790286
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis - a Northern European perspective.
Bachert C; Vestenbaek U; Christensen J; Griffiths UK; Poulsen PB
Clin Exp Allergy; 2007 May; 37(5):772-9. PubMed ID: 17456225
[TBL] [Abstract][Full Text] [Related]
40. Sublingual immunotherapy for Japanese cedar pollinosis.
Okubo K; Gotoh M
Allergol Int; 2009 Jun; 58(2):149-54. PubMed ID: 19390236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
